21 – 30 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study
(
- Contribution to journal › Article
-
Mark
Monoclonal Gammopathy of Undetermined Significance and Risk of Infections A Population Based Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group
(
- Contribution to journal › Article
-
Mark
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
(
- Contribution to journal › Article
-
Mark
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
(
- Contribution to journal › Article
- 2009
-
Mark
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Risk of plasma cell and lymphoproliferative disorders among 14 621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden
(
- Contribution to journal › Article
-
Mark
Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study
(
- Contribution to journal › Article
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract